BCL2 and plasma cell myeloma: Bortezomib requires caspase-8 and caspase-9, whereas marizomib induces the apoptotic effect mainly through caspase-8 signaling that allows it to overcome the resistance of myeloma cells conferred by Bcl-2 mutations [97, 98].